Netherlands Translational Research Center B.V.

What Netherlands Translational Research Center B.V. does

Netherlands Translational Research Center B.V. ("NTRC") is a privately held Dutch translational research organization founded in 2011 and headquartered in Oss, Netherlands. The company is structured as a besloten vennootschap (B.V.), the Dutch private limited liability form, and operates with 11-50 employees. Its stated mission is to translate novel biological concepts on the treatment of diseases into small molecule drugs, effectively functioning as a contract research and drug discovery services provider bridging academic biology and pharmaceutical development.

NTRC's commercial portfolio is organized around two subdomain platforms. NTRCtx (www.ntrctx.com) is positioned as the company's translational research platform focused on cancer research applications, providing the core translational pipeline through which biological concepts are converted into small molecule drug candidates. Oncolines (www.oncolines.com) is a product brand focused on oncology research assays and services, offering specialized cell-line and assay-based research tools to drug discovery clients. Together, these two platforms suggest a horizontal, service-oriented business model targeting academic research institutions and pharmaceutical companies requiring translational research support in oncology and related therapeutic areas.

The company operates a fee-for-service and collaborative research model typical of European boutique CROs, though no pricing structures, contract terms, or revenue figures are publicly disclosed. Customer acquisition channels, partnerships, and management team are not disclosed in the available material. The only documented capital event is a small 2015 funding round of approximately $60,230 from the European Innovation Council SME instrument (EISMEA), which is likely a non-dilutive innovation grant rather than a venture financing. This points to a lean, self-funded or largely self-funded operating model with modest external capital.

Name

Netherlands Translational Research Center B.V.

Legal name

Netherlands Translational Research Center B.V.

Website

https://ntrc.nl

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Netherlands Translational Research Center B.V. (NTRC) is a privately held Dutch translational research organization that translates novel biological concepts into small molecule drugs for cancer research, serving academic institutions and pharmaceutical companies via its NTRCtx and Oncolines platforms.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Drug discovery services
• Translational research
• Small molecule therapeutics
• Oncology research assays
• Pharmaceutical R&D

Headquarters

HQ city

Oss

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Netherlands Translational Research Center (NTRC) translates novel biological concepts on the treatment of diseases into small molecule drugs. The company operates two specialized research platforms—NTRCtx, focused on translational research for cancer research applications, and Oncolines, focused on oncology research assays and services—serving academic research institutions and pharmaceutical companies.

Product overview

NTRC – Netherlands Translational Research Center operates as a translational research organization offering specialized research products and services. The company provides two named product offerings: NTRCtx (available at www.ntrctx.com) and Oncolines (available at www.oncolines.com), both accessible through their main website. The portfolio appears to focus on cancer research applications.

Differentiator

Problem solved

Functional benefit

Brands

• NTRCtx: A website operated by NTRC, referenced via www.ntrctx.com
• Oncolines

Products and services

• NTRCtx NTRC's translational research platform focused on cancer research applications, supporting the translation of novel biological concepts into small molecule drugs. Targeted at academic research institutions and pharmaceutical companies.
• Oncolines NTRC's product brand focused on oncology line of research assays and services for cancer drug discovery and development. Targeted at academic research institutions and pharmaceutical companies.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Direct peers

• Evotec: Global drug-discovery CRO offering translational research and small-molecule discovery services to pharma and biotech. Directly comparable to NTRC's translational/small-molecule drug discovery positioning.
• Sygnature Discovery: Independent drug-discovery CRO with strong medicinal chemistry and translational capabilities serving pharma clients. Directly comparable service model to NTRC.
• Mercachem: Dutch CRO based in Oss offering medicinal chemistry and small-molecule drug discovery services. Same city and a very similar service portfolio, making it a directly comparable peer.
• Crown Bioscience: Oncology-focused CRO providing preclinical research services and translational oncology platforms. Comparable to NTRC's oncology research assays/services orientation.
• Revvity (formerly Horizon Discovery): Provides cell-line engineering, functional genomics, and translational research tools widely used in oncology drug discovery. Comparable as a discovery-tools and translational-services peer.
• GenScript: Biotech services provider offering gene synthesis, cell-line engineering, and drug-discovery support tools. Comparable as a research-tools/services peer in early-stage discovery.

Regional players

• Pivot Park Screening Centre: Drug-discovery screening centre also based in Oss, Netherlands. Operates in the same local cluster and offers adjacent translational/screening services, making it a relevant regional comparable.

Broad incumbents

• Charles River Laboratories: Large, established CRO with broad discovery and translational research offerings including oncology services. Competes with NTRC but at much greater scale and breadth.
• Pharmaron: Integrated CRO offering drug discovery, medicinal chemistry, and translational research services across multiple therapeutic areas. Overlaps NTRC's discovery services on a larger scale.
• WuXi AppTec: Global CRO/CDMO offering small-molecule discovery and translational research services. Overlaps with NTRC's offerings but operates at vastly larger scale.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Netherlands Translational Research Center B.V.